questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
NADH, NADPH oxidoreductases
NADH, NADPH oxidoreductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Combined Modality Therapy
Diagnostic
5
Déficience enzymatique
Tests génétiques
Fatigue
Troubles métaboliques
Activité enzymatique
Évaluation fonctionnelle
Anomalies génétiques
Mutations
Symptômes
5
Déficience en NADPH
Infections fréquentes
Troubles neurologiques
Dysfonctionnement enzymatique
Troubles digestifs
Métabolisme énergétique
Prévention
5
Alimentation équilibrée
Nutriments essentiels
Mode de vie sain
Exercice
Bilans de santé
Anomalies enzymatiques
Éducation nutritionnelle
Carences
Traitements
5
Suppléments enzymatiques
Modifications diététiques
Thérapie génique
Déficiences enzymatiques
Médicaments
Modulation enzymatique
Transfusions sanguines
Déficiences
Complications
5
Complications
Troubles métaboliques
Infections
Déficiences enzymatiques
Maladies chroniques
Diabète
Complications cardiovasculaires
Troubles métaboliques
Complications hématologiques
Métabolisme
Facteurs de risque
5
Antécédents familiaux
Maladies métaboliques
Mode de vie sédentaire
Mauvaise alimentation
Maladies génétiques
Prédisposition
Stress oxydatif
Déficiences enzymatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "NADH, NADPH oxidoreductases : Questions médicales les plus fréquentes",
"headline": "NADH, NADPH oxidoreductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les NADH, NADPH oxidoreductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-05",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "NADH, NADPH oxidoreductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxidoreductases",
"url": "https://questionsmedicales.fr/mesh/D010088",
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases",
"code": {
"@type": "MedicalCode",
"code": "D010088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome reductases",
"alternateName": "Cytochrome Reductases",
"url": "https://questionsmedicales.fr/mesh/D003579",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome reductases",
"code": {
"@type": "MedicalCode",
"code": "D003579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.191"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADPH-ferrihemoprotéine reductase",
"alternateName": "NADPH-Ferrihemoprotein Reductase",
"url": "https://questionsmedicales.fr/mesh/D009251",
"about": {
"@type": "MedicalCondition",
"name": "NADPH-ferrihemoprotéine reductase",
"code": {
"@type": "MedicalCode",
"code": "D009251",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.191.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "NADH tetrazolium reductase",
"alternateName": "NADH Tetrazolium Reductase",
"url": "https://questionsmedicales.fr/mesh/D009246",
"about": {
"@type": "MedicalCondition",
"name": "NADH tetrazolium reductase",
"code": {
"@type": "MedicalCode",
"code": "D009246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.530"
}
}
},
{
"@type": "MedicalWebPage",
"name": "NADP transhydrogenases",
"alternateName": "NADP Transhydrogenases",
"url": "https://questionsmedicales.fr/mesh/D009250",
"about": {
"@type": "MedicalCondition",
"name": "NADP transhydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D009250",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.540"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADP transhydrogenase, AB-specific",
"alternateName": "NADP Transhydrogenase, AB-Specific",
"url": "https://questionsmedicales.fr/mesh/D061087",
"about": {
"@type": "MedicalCondition",
"name": "NADP transhydrogenase, AB-specific",
"code": {
"@type": "MedicalCode",
"code": "D061087",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.540.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "NADPH dehydrogenase",
"alternateName": "NADPH Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D009252",
"about": {
"@type": "MedicalCondition",
"name": "NADPH dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D009252",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Quinone reductases",
"alternateName": "Quinone Reductases",
"url": "https://questionsmedicales.fr/mesh/D011808",
"about": {
"@type": "MedicalCondition",
"name": "Quinone reductases",
"code": {
"@type": "MedicalCode",
"code": "D011808",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADPH dehydrogenase (quinone)",
"alternateName": "NAD(P)H Dehydrogenase (Quinone)",
"url": "https://questionsmedicales.fr/mesh/D016660",
"about": {
"@type": "MedicalCondition",
"name": "NADPH dehydrogenase (quinone)",
"code": {
"@type": "MedicalCode",
"code": "D016660",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.800.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "NADH, NADPH oxidoreductases",
"alternateName": "NADH, NADPH Oxidoreductases",
"code": {
"@type": "MedicalCode",
"code": "D009247",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fei-Long Li",
"url": "https://questionsmedicales.fr/author/Fei-Long%20Li",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Ye-Wang Zhang",
"url": "https://questionsmedicales.fr/author/Ye-Wang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China; College of Petroleum and Chemical Engineering, Beibu Gulf University, Qinzhou 535011, People's Republic of China. Electronic address: zhangyewang@ujs.edu.cn."
}
},
{
"@type": "Person",
"name": "Chuanwu Xia",
"url": "https://questionsmedicales.fr/author/Chuanwu%20Xia",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA."
}
},
{
"@type": "Person",
"name": "Anna L Shen",
"url": "https://questionsmedicales.fr/author/Anna%20L%20Shen",
"affiliation": {
"@type": "Organization",
"name": "McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53706, USA."
}
},
{
"@type": "Person",
"name": "Jung-Ja P Kim",
"url": "https://questionsmedicales.fr/author/Jung-Ja%20P%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. Electronic address: jjkim@mcw.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.",
"datePublished": "2023-08-06",
"url": "https://questionsmedicales.fr/article/37586927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clcc.2023.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.",
"datePublished": "2022-11-09",
"url": "https://questionsmedicales.fr/article/36351568",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14724"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.",
"datePublished": "2022-07-17",
"url": "https://questionsmedicales.fr/article/35963771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clml.2022.07.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.",
"datePublished": "2022-09-05",
"url": "https://questionsmedicales.fr/article/36102865",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/DCR.0000000000002600"
}
},
{
"@type": "ScholarlyArticle",
"name": "PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).",
"datePublished": "2022-09-10",
"url": "https://questionsmedicales.fr/article/36099671",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2022.07.027"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "NADH, NADPH oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D009247"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : NADH, NADPH oxidoreductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur NADH, NADPH oxidoreductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur NADH, NADPH oxidoreductases",
"description": "Comment diagnostiquer une déficience en NADH oxydoréductases ?\nQuels tests sanguins sont utiles pour évaluer NADPH ?\nQuels symptômes indiquent un problème avec ces enzymes ?\nLes tests d'activité enzymatique sont-ils fiables ?\nPeut-on détecter des anomalies génétiques liées à ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur NADH, NADPH oxidoreductases",
"description": "Quels sont les symptômes d'une carence en NADH ?\nComment se manifeste une déficience en NADPH ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nDes symptômes digestifs peuvent-ils apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur NADH, NADPH oxidoreductases",
"description": "Comment prévenir les déficiences en NADH ?\nY a-t-il des habitudes de vie à adopter ?\nLes bilans de santé réguliers sont-ils utiles ?\nLes vaccinations peuvent-elles jouer un rôle ?\nL'éducation nutritionnelle est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur NADH, NADPH oxidoreductases",
"description": "Quels traitements existent pour les déficiences enzymatiques ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à réguler ces enzymes ?\nY a-t-il des traitements naturels recommandés ?\nLes transfusions sanguines sont-elles nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur NADH, NADPH oxidoreductases",
"description": "Quelles complications peuvent survenir avec une déficience en NADH ?\nLes infections sont-elles une complication fréquente ?\nY a-t-il des risques de maladies chroniques ?\nLes complications cardiovasculaires sont-elles possibles ?\nDes complications hématologiques peuvent-elles survenir ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur NADH, NADPH oxidoreductases",
"description": "Quels facteurs de risque sont associés aux déficiences enzymatiques ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies génétiques sont-elles un facteur ?\nLe stress oxydatif joue-t-il un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en NADH oxydoréductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour évaluer NADPH ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages de NADPH et d'autres coenzymes dans le sang peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire et troubles métaboliques peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Les tests d'activité enzymatique sont-ils fiables ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent utilisés pour évaluer la fonction des NADH et NADPH oxydoréductases."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies génétiques liées à ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier des mutations affectant ces enzymes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en NADH ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles cognitifs et faiblesse musculaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une déficience en NADPH ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des infections fréquentes et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en cas de dysfonctionnement enzymatique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état de santé général."
}
},
{
"@type": "Question",
"name": "Des symptômes digestifs peuvent-ils apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles digestifs peuvent être liés à des anomalies dans le métabolisme énergétique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les déficiences en NADH ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en nutriments essentiels peut aider à prévenir ces déficiences."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain incluant exercice et gestion du stress est recommandé."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers peuvent aider à détecter précocement des anomalies enzymatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles jouer un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les déficiences."
}
},
{
"@type": "Question",
"name": "L'éducation nutritionnelle est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre l'importance des nutriments peut aider à prévenir les carences."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à réguler ces enzymes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à moduler l'activité des NADH et NADPH oxydoréductases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antioxydants et des nutriments peuvent soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas graves, des transfusions peuvent être nécessaires pour corriger des déficiences."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en NADH ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences enzymatiques sont plus susceptibles aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déficiences peuvent augmenter le risque de maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles métaboliques peuvent entraîner des complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Des complications hématologiques peuvent-elles survenir ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le métabolisme peuvent entraîner des complications hématologiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux déficiences enzymatiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies métaboliques et une mauvaise nutrition."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent être plus fréquentes chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques prédisposent aux déficiences en NADH et NADPH."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif joue-t-il un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut aggraver les déficiences enzymatiques et leurs effets."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 01/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China; College of Petroleum and Chemical Engineering, Beibu Gulf University, Qinzhou 535011, People's Republic of China. Electronic address: zhangyewang@ujs.edu.cn.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53706, USA.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. Electronic address: jjkim@mcw.edu.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Biochemistry, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Biochemistry, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Biochemistry, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Publications dans "NADH, NADPH oxidoreductases" :
2 publications dans cette catégorie
Affiliations :
Department of Physics, Miami University, Oxford, OH 45056, USA.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Vorobievy Gory 1/40, Moscow 119234, Russia.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Vorobievy Gory 1/40, Moscow 119234, Russia.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Vorobievy Gory 1/40, Moscow 119234, Russia.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Institut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 8 Allée Gaspard Monge, 67000 Strasbourg, France. rjmayer@unistra.fr.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Institut de Science et d'Ingénierie Supramoléculaires (ISIS), CNRS UMR 7006, Université de Strasbourg, 8 Allée Gaspard Monge, 67000 Strasbourg, France. rjmayer@unistra.fr.
Institut Universitaire de France (IUF), 75005 Paris, France.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Albert-Ludwigs-Universität Freiburg, Institut für Biochemie, Albertstr. 21, D-79104 Freiburg, Germany.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Albert-Ludwigs-Universität Freiburg, Institut für Biochemie, Albertstr. 21, D-79104 Freiburg, Germany.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
Albert-Ludwigs-Universität Freiburg, Institut für Biochemie, Albertstr. 21, D-79104 Freiburg, Germany. Electronic address: friedrich@bio.chemie.uni-freiburg.de.
Publications dans "NADH, NADPH oxidoreductases" :
1 publication dans cette catégorie
Affiliations :
School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China.
Publications dans "NADH, NADPH oxidoreductases" :
Survival rates in early-stage rectal cancer patients have increased over the past few decades. Societies such as the National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), Americ...
We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC)....
This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s...
Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ...
Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...
The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria...
This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe...
We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi...
For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....
There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer....
This study aimed to evaluate long-term changes in patients treated with combined modality....
This was a retrospective study of prospectively collected patient-reported outcome surveys....
This study was conducted at a single institution....
There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey....
This study included patient-reported outcomes reflecting bowel, sexual, and urinary function....
Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9...
This was a single-institution study and only patients who answered the questionnaire were included in the study....
A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was...
ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...
Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder...
Patients underwent baseline...
In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien...
The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder...
NCT00002014-000860-16....
Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often...
To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans....
This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ...
Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme...
Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...
Monotherapy with autologous expanded CD4...
We conducted a three-arms clinical trial to explore the efficacy and safety of the combined treatment with Tregs and rituximab in paediatric patients with T1DM. The patients were allocated to three gr...
At month 24, as compared with the control, both treatment groups remained superior in the area under the curve of C-peptide mixed meal tolerance test, whereas in the analysis of all visits only the co...
Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission....
Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti...
Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel...
Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...
Loop diuretics are the cornerstone of the treatment of volume overload in decompensated heart failure. However, often complete decongestion cannot be achieved rapidly with loop diuretics alone, partly...
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma (HCC). The synergistic effect of systemic therapy and radia...
This retrospective observational study analyzed the medical records of 194 patients with Barcelona Clinic Liver Cancer stage C HCC who were admitted to our center from August 2018 to June 2022 and rec...
A total of 76 patients diagnosed with advanced-stage HCC and treated with ICIs and antiangiogenic therapy were included in the study, with 33 patients in the RT group and 43 patients in the non-RT gro...
In comparison to the combination of ICIs and antiangiogenic therapy, the inclusion of RT has been observed to improve the DCR and survival outcomes in patients with advanced-stage HCC. The safety prof...